Why treat just the signs of canine osteoarthritis when you can proactively treat the disease?

Special diets, supplements and anti-inflammatory drugs can play a part in managing joint disease but none of them specifically address the underlying cartilage deterioration. Once cartilage wears away completely, it can’t be restored so it’s vital to help maintain its use.1 That’s what makes Adequan® Canine (polysulfated glycosaminoglycan) different. It empowers you to proactively treat the disease and not just the signs of canine osteoarthritis.2

Adequan Canine canine joint damage

INDICATIONS Adequan® Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.

How To Use Graph How To Use Graph

The one joint prescription
that works differently.

Adequan® Canine is the only FDA-approved disease-modifying osteoarthritis drug (DMOAD) that inhibits cartilage loss in a dog’s joints.2

The specific mechanism of action of Adequan® in canine joints is not known.2

Discover if Adequan® Canine is the right choice.

Know the early signs of OA.

The first signs of OA often appear as subtle changes in a dog’s behavior. Left unrecognized and untreated, degenerative joint disease can progress to more severe signs that can adversely affect long-term mobility. Some of the early warning signs include:3,4

  • Unusual body positions when resting or sleeping
  • Struggles to get comfortable - frequently changes positions
  • Stiff, slow or shaky when getting up
  • Shifts weight while standing
  • Reluctant to sit, walk or climb stairs
  • Has trouble squatting to eliminate

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Adequan® Canine brand of polysulfated glycosaminoglycan (PSGAG)
INDICATIONS Adequan® Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.
IMPORTANT SAFETY INFORMATION Adequan® Canine should not be used in dogs who are hypersensitive to PSGAG or who have a known or suspected bleeding disorder. It should be used with caution in dogs with renal or hepatic impairment. Adverse reactions in clinical studies (transient pain at injection site, transient diarrhea, and abnormal bleeding) were mild and self-limiting. In post approval experience, death has been reported in some cases; vomiting, anorexia, depression/lethargy and diarrhea have also been reported. The safe use of PSGAG in breeding, pregnant or lactating dogs has not been evaluated. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For additional safety information, please see Full Prescribing Information.
1. 2016 NAVC Proceedings, Osteoarthritis in Dogs and Cats: Novel Therapeutic Advances, M Epstein, DVM, DABVP C/F, CVPP; K Kirkby-Shaw, DVM, MS, PhD, DACVS, DACVSMR.
2. Adequan® Canine Package Insert, Rev 1/19.
3. Clinician’s Brief, Aug 2013, Canine OA, DA Canapp, DVM, CCRT, CVA, DACVSMR.
4. Face validity of a proposed tool for staging canine osteoarthritis: Canine Osteoarthritis Staging Tool (COAST), T. Cachon, O. Frykman, J.F. Innes, B.D.X. Lascelles, M. Okumura, P. Sousa, F. Staffieri, P.V. Steagall, B. Van Ryssen, COAST Development Group, The Veterinary Journal, 235 (2018) 1-8.

Let’s stay in touch.

Be the first to hear about important news and product information!
First, select the one that best describes you.
Then we'll take you to our sign-up page.

CANINE VETERINARY
PROFESSIONAL		 DOG OWNER
CONTACT INFORMATION
Contact Us Adverse Event Reporting Product Quality Complaints Sign Up
ABOUT ADEQUAN® CANINE
Dosing & Administration Prescribing Information Safety Information Ordering Information
AMERICAN REGENT ANIMAL HEALTH
About Us Our Brands
©2020, American Regent, Inc.
Adequan is a registered trademark and the Dog Head design is a trademark of America Regent, Inc.
PP-AC-US-0102 (v3.0) 07/2020